Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Male gender, initial shockable rhythm tied to favourable neurological outcomes after cardiac arrest

15 Nov 2018

In adult cardiac arrest (CA) patients treated with targeted temperature management (TTM), male sex, bystander cardiopulmonary resuscitation (CPR) and the presence of initial shockable rhythm all correlate with greater chances of favourable neurological outcomes, a recent meta-analysis has shown.

A total of 17 studies were eligible for inclusion in the analysis after searching PubMed, Embase and the Cochrane Library databases. Quality assessment scores ranged from 6–9, suggesting fairness and a good risk of bias.

Pooled analysis showed that initial shockable cardiac rhythm correlated with a significantly higher odds of good neurological outcomes at hospital discharge (odds ratio [OR], 7.63; 95 percent CI, 6.51–8.96; p<0.00001), with no significant heterogeneity of evidence (p=0.73).

Moreover, survivors were significantly more likely than nonsurvivors to have shockable cardiac rhythm as first recorded rhythm (OR, 4.88; 3.18–4.79; p<0.00001).

Similarly, bystander CPR was associated with significantly higher chances of favourable neurological outcomes (OR, 1.44; 1.14-1.82; p=0.003), though significant heterogeneity in evidence was reported (p=0.01).

Participant sex likewise played an important role. Survivors were more likely to be male than female (OR, 1.36; 0.99–1.88; p=0.06), but the results were only of borderline significance. Additionally, male sex was significantly correlated with favourable neurological outcomes at discharge (OR, 1.39; 1.20–1.61; p<0.00001).

The present findings “would help in making individualized decisions concerning patients’ eligibility for starting or continuing TTM,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.